Accelrys to Provide Contract Research for Homeland Security Project.

SAN DIEGO -- Accelrys, Inc. (NASDAQ:ACCL) today announced a subcontract agreement with the Northrop Grumman Corp. to assist in the research and development of bioagent detectors for the U.S. Department of Homeland Security (DHS).

Under the agreement, Accelrys will employ its proprietary technology in statistical modeling and analysis to help determine the anticipated sensitivity and selectivity of the detection tools, which will be used to monitor for the presence of bacteria, viruses and toxin-proteins. Accelrys software applications that may be utilized include those that employ mathematical algorithms to predict a substance's activity based on its structural and genetic properties.

Northrop Grumman was one of 14 companies and universities contracted by the Homeland Security Advance Research Projects Agency (HSARPA) to research and develop measures for defending against biological threats. During the initial 18-month phase of this project, $48 million will be awarded to the contracted teams. Northrop Grumman will be participating in the effort to develop Bioagent Autonomous Networked Detectors (BAND), which will be used to continuously monitor for bioagents in outdoor urban areas.

"Accelrys is pleased to be a part of this important research endeavor," Katie Hollister, Accelrys' VP client services, commented. "The award of the contract is a significant milestone for Accelrys' contract research services division. We look forward to working closely with Northrop Grumman and the rest of the team for the duration of this HSARPA project."

About Accelrys, Inc.

Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, simulation and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego. For more information about Accelrys, visit its Web site at http://www.accelrys.com/.

When used anywhere in this document, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Accelrys. Accelrys has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Accelrys' strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions and other risks described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.